Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Cash & equivalents changed -74.4% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Operating income changed -67.7% from the comparable as-filed period.
Free-cash-flow proxy changed -40.2% from the comparable as-filed period.
Operating cash flow changed -40.1% from the comparable as-filed period.
Working capital / assets changed -1444 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Current assets changed -34.2% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Current ratio changed -41.8% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Working capital changed -36.3% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Research & development changed +90.7% from the comparable as-filed period.
Capital expenditure changed +108.9% from the comparable as-filed period.
Current liabilities changed +13.1% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Total assets changed -24.3% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Stock-based compensation changed +41.5% from the comparable as-filed period.
Stock-based compensation changed +6.8% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Research & development changed +33.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed -28.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed -19.7% from the comparable as-filed period.
Cash & equivalents changed +56.8% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.